Clinical Trials Logo

Head and Neck Cancer clinical trials

View clinical trials related to Head and Neck Cancer.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05395052 Terminated - Breast Cancer Clinical Trials

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Start date: May 31, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose-finding study of FT536 given in combination with a monoclonal antibody following lymphodepletion in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

NCT ID: NCT05265013 Terminated - Clinical trials for Head and Neck Cancer

ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

Start date: April 19, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 Single-arm Study of ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck, With or Without Metastases, Not Amenable to Curative Local Treatment

NCT ID: NCT05061940 Terminated - Clinical trials for Head and Neck Cancer

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Start date: May 5, 2021
Phase:
Study type: Observational

The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.

NCT ID: NCT05061537 Terminated - Colorectal Cancer Clinical Trials

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Start date: October 20, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 [PD-1] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them. The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

NCT ID: NCT04936841 Terminated - Clinical trials for Head and Neck Cancer

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Start date: August 5, 2021
Phase: Phase 2
Study type: Interventional

This trial will evaluate safety and efficacy of the combination of anti-PD1, NKTR-214, and palliative radiation therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Twenty-four participants will be enrolled to evaluate the efficacy of this combination.

NCT ID: NCT04880603 Terminated - Clinical trials for Head and Neck Cancer

Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site

Start date: April 5, 2021
Phase: Phase 2
Study type: Interventional

Adult patients undergoing a radial forearm free flap or ulnar forearm free flap will be randomized to the use of the Restrata graft in combination with split-thickness skin graft for reconstruction. Photos will document whether the Restata graft aids in the healing.

NCT ID: NCT04682431 Terminated - Breast Cancer Clinical Trials

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Start date: November 10, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).

NCT ID: NCT04672980 Terminated - Clinical trials for Head and Neck Cancer

RTX-321 Monotherapy in Patients With HPV 16+ Tumors

Start date: April 8, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, multiple-ascending dose, FIH, Phase 1 study of RTX-321 for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or metastatic, unresectable, HPV 16+ cancers.

NCT ID: NCT04634825 Terminated - Clinical trials for Head and Neck Cancer

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Start date: March 17, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

NCT ID: NCT04268329 Terminated - Clinical trials for Head and Neck Cancer

Evaluating the Use of an Informational Head and Neck Cancer Website.

Start date: August 16, 2016
Phase: N/A
Study type: Interventional

It can be difficult for head and neck cancer patients and their families to fully understand the impact that cancer procedures and treatments can have on the cancer patients life. Procedures used to treat head and neck cancer may result in significant changes to the patients' physical appearance and/or functional abilities (talking, eating, and breathing). The lack of understanding as it relates to the effects of cancer treatments can have a significant impact on the patients post-operative success. In an effort to help educate head and neck cancer patients and their families during this difficult time, the UIC department of Otolaryngology-HNS has created an informational website. The website is designed to educate cancer patients and their families regarding various cancer treatments and therapies.